SAN DIEGO, July 9, 2015 /PRNewswire/ -- Organovo
Holdings, Inc. (NYSE MKT: ONVO; "Organovo"), a three-dimensional
biology company focused on delivering scientific and medical
breakthroughs using 3D bioprinting technology, announced today that
the July 8th presentation given by President and
CEO Keith Murphy at Cantor Fitzgerald Inaugural
Healthcare Conference is now available via a webcast replay
for the next 90 days.
To access the webcast, register at:
http://wsw.com/webcast/cantor2/onvo. During the playback, the
listener can advance the slides manually using the buttons provided
at the upper right of the screen.
Organovo's 3D bioprinting enables the reproducible, automated
creation of living human tissues that mimic the form and function
of native tissues in the body. The company recently announced
collaborations with L'Oreal to produce skin tissue for research and
toxicity testing; with Merck to print liver and kidney tissues for
studies of drug toxicity and with Yale School
of Medicine to develop 3-D organ tissues for surgical
transplantation research. Organovo was named one of The
World's Top 10 Most Innovative Companies of 2015 in Health Care by
Fast Company.
The Cantor Fitzgerald conference presentation is targeted
towards current information regarding the Company. An
overview of Organovo's 3D bioprinting technology and company
background is available via video presentation at the Company's
website: http://www.organovo.com/investors/investor-overview.
About Organovo Holdings, Inc.
Organovo designs and creates functional, three-dimensional human
tissues for use in medical research and therapeutic applications.
The Company develops 3D human disease models through internal
development and in collaboration with pharmaceutical and academic
partners. Organovo's 3D human tissues have the potential to
accelerate the drug discovery process, enabling treatments to be
developed faster and at lower cost. The company recently launched
its initial product of the planned exVive3DTM portfolio
offering, a 3D Human Liver Tissue for use in Toxicology and other
preclinical drug testing. Additional products are in development,
with anticipated release for an exVive3D™ Human Kidney Tissue in
the latter half of calendar year 2016. The Company also actively
conducts early research on specific tissues for therapeutic use in
direct surgical applications. In addition to numerous scientific
publications, the Company's technology has been featured in The
Wall Street Journal, Time Magazine, The Economist, and numerous
other media outlets. Organovo is changing the shape of medical
research and practice. Learn more at www.organovo.com.
Sign up for email updates and connect with us
on Twitter (@Organovo).
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/organovo-holdings-incs-presentation-at-cantor-fitzgerald-inaugural-healthcare-conference-now-available-via-webcast-replay-300110734.html
SOURCE Organovo Holdings, Inc.